Arecor Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AREC.L research report →
Companywww.arecor.com
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection.
- CEO
- Sarah Jennifer Howell
- IPO
- 2021
- Employees
- 50
- HQ
- Little Chesterford, GB
Price Chart
Valuation
- Market Cap
- $25.67M
- P/E
- 38.67
- P/S
- 14.98
- P/B
- 3.98
- EV/EBITDA
- -5.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 61.32%
- Op Margin
- -268.49%
- Net Margin
- 38.74%
- ROE
- 14.26%
- ROIC
- -65.51%
Growth & Income
- Revenue
- $1.71M · -66.08%
- Net Income
- $664.00K · 106.49%
- EPS
- $0.02 · 105.68%
- Op Income
- $-4,602,000
- FCF YoY
- 73.97%
Performance & Tape
- 52W High
- $100.00
- 52W Low
- $40.00
- 50D MA
- $66.67
- 200D MA
- $73.21
- Beta
- -0.21
- Avg Volume
- 17.49K
Get TickerSpark's AI analysis on AREC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AREC.L Coverage
We haven't published any research on AREC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AREC.L Report →